Stemtech Corp (STEK) — SEC Financial Statements & Analysis

Stemtech Corp (STEK) is a wholesale-drugs, proprietaries & druggists' sundries company. Stemtech Corp trades on OTC as: STEK. Stemtech Corp (STEK)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Stemtech Corp carries a market cap of $207.74K, a P/E ratio of -0.05x, a P/B ratio of -0.03x, a P/S ratio of 0.09x, an enterprise value of $4.36M, and an EV/EBITDA multiple of -1.93x. On profitability, it posts a gross margin of 77.27%, an operating margin of -100.84%, a net margin of -160.09%, a Return on Equity (ROE) of 55.25%, and a Return on Assets (ROA) of -109.34%. Per share, it reports EPS of $-0.00, diluted EPS of $-0.00, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -16.91% year-over-year, net income growth of 51.86% year-over-year, and EPS growth of -89.59% year-over-year. On the balance sheet, it maintains a current ratio of 0.05x, a quick ratio of 0.02x, working capital of $-10.54M, a debt-to-equity ratio of -1.49x, a debt ratio of 3.51, an interest coverage ratio of -1.81x, free cash flow of $-328.75K (TTM), and net debt of $4.15M. Figures sourced from SEC EDGAR.

Market Cap

$207.74K

P/E TTM

-0.05x

EPS TTM

$-0.00

P/B TTM

-0.03x

ROE TTM

55.25%

ROA TTM

-109.34%

Debt To Equity

-1.49x

Free Cash Flow TTM

$-328.75K

Net Revenue TTM Growth 1Y

-16.91%

Data as of 2026-06-30 · Source: SEC EDGAR